Reaffirmed: miRagen Therapeutics Inc (MGEN) “Buy” Rating Kept at Wedbush; $19.0 Target in Place

March 14, 2018 - By Linda Rogers

 Reaffirmed: miRagen Therapeutics Inc (MGEN)

miRagen Therapeutics Inc (MGEN) Rating Reaffirmed

In an analyst note released this morning, Wedbush maintained their “Buy” rating on miRagen Therapeutics Inc (MGEN) shares. The target price per share indicates a possible upside of 168.74 % from company’s last stock price.

Miragen Therapeutics, Inc. (NASDAQ:MGEN) Ratings Coverage

Among 7 analysts covering Miragen Therapeutics (MGEN), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Miragen Therapeutics has $19.0 highest and $13.0 lowest target. $16.40’s average target is 131.97% above currents $7.07 stock price. Miragen Therapeutics had 11 analyst reports since February 21, 2017 according to SRatingsIntel. Wedbush initiated it with “Outperform” rating and $19.0 target in Tuesday, February 21 report. The rating was maintained by Wedbush with “Buy” on Friday, August 18. The rating was initiated by Oppenheimer on Thursday, January 11 with “Buy”. The company was maintained on Friday, February 2 by FBR Capital. The stock of Miragen Therapeutics, Inc. (NASDAQ:MGEN) has “Buy” rating given on Monday, August 14 by Chardan Capital Markets. The rating was maintained by Wedbush with “Buy” on Monday, October 16. The firm has “Buy” rating given on Friday, December 1 by Wedbush.

The stock increased 0.71% or $0.05 during the last trading session, reaching $7.07. About 223,355 shares traded. Miragen Therapeutics, Inc. (MGEN) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. The company has market cap of $207.16 million. The Company’s two lead product candidates, MRG-106 and MRG-201 are in Phase 1 clinical trials. It currently has negative earnings. The companyÂ’s clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in various blood cancers.

More notable recent Miragen Therapeutics, Inc. (NASDAQ:MGEN) news were published by: which released: “miRagen Therapeutics to Present at the Cantor Fitzgerald Global Healthcare …” on September 01, 2017, also with their article: “miRagen Therapeutics to Announce Third Quarter 2017 Financial Results and Host …” published on November 01, 2017, published: “miRagen Therapeutics, Inc. Prices Public Offering of Common Stock” on February 08, 2018. More interesting news about Miragen Therapeutics, Inc. (NASDAQ:MGEN) were released by: and their article: “miRagen Therapeutics to Report Fourth Quarter and Full Year 2017 Financial …” published on March 07, 2018 as well as‘s news article titled: “miRagen Therapeutics (MGEN) Announces Proposed 7M Share Common Offering” with publication date: February 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.